再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 05-01 16:00:00 EDT

701.42

-5.64

-0.80%

盘后702.10

+0.68+0.10%

19:55 EDT

最高714.48	最低700.26	成交量72.92万
今开703.02	昨收707.06	日振幅2.01%
总市值741.54亿	流通市值724.59亿	总股本1.06亿
成交额5.14亿	换手率0.71%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":701.42,"timestamp":1777665600000,"preClose":707.06,"halted":0,"volume":729185,"hourTrading":{"tag":"盘后","latestPrice":702.1,"preClose":701.42,"latestTime":"19:55 EDT","volume":29839,"amount":20931067.7013,"timestamp":1777679709654,"change":0.68,"changeRate":0.000969,"amplitude":0.003678},"delay":0,"changeRate":-0.007976692218482146,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"休市中","change":-5.64,"latestTime":"05-01 16:00:00 EDT","open":703.02,"high":714.48,"low":700.2594,"amount":513719509.80149996,"amplitude":0.020112,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":707.06,"dividendRate":0.005258,"preHourTrading":{"tag":"盘前","latestPrice":700.31,"preClose":707.06,"latestTime":"09:27 EDT","volume":655,"amount":462298.4105,"timestamp":1777642070010,"change":-6.75,"changeRate":-0.009547,"amplitude":0.014483},"postHourTrading":{"tag":"盘后","latestPrice":702.1,"preClose":701.42,"latestTime":"19:55 EDT","volume":29839,"amount":20931067.7013,"timestamp":1777679709654,"change":0.68,"changeRate":0.000969,"amplitude":0.003678},"volumeRatio":0.7435672735045231,"impliedVol":0.3482,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1157184372","title":"再生元制药公司将下调医疗补助药品价格 未来美国药价拟与国际接轨","url":"https://stock-news.laohu8.com/highlight/detail?id=1157184372","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157184372?lang=zh_cn&edition=full","pubTime":"2026-04-24 03:49","pubTimestamp":1776973774,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，将下调其药品在医疗补助计划中的定价，并计划未来使美国市场的药品价格与其他国家保持一致。\n这一战略调整标志着该生物技术巨头在定价政策上的重大转变。公司表示，通过降低医疗补助价格，将提升药品可及性；而与国际价格接轨的长期目标，则旨在应对美国国内关于药价过高的持续批评。\n分析人士指出，此举可能对生物制药行业产生深远影响，或促使其他企业重新评估其定价模式。再生元的核心产品包括治疗眼疾的Eylea和湿疹药物Dupixent，这些重磅药物在美国市场的定价一直备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0289739699.SGD","LU0882574055.USD","LU0053666078.USD","LU2237438978.USD","LU2023250504.SGD","BK4139","LU0823434583.USD","LU2362540622.SGD","REGN","LU2106854487.HKD","LU0114720955.EUR","LU2362541513.USD","LU2089984988.USD","LU0109394709.USD","LU0320765992.SGD","LU2362541273.HKD","BK4585","LU1917777945.USD","LU0823416689.USD","LU0823434740.USD","BK4588","LU0058720904.USD","LU0889565916.HKD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111940710","title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1111940710","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111940710?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:06","pubTimestamp":1776820018,"startTime":"0","endTime":"0","summary":"再生元制药公司将于2026年04月29日发布业绩，市场关注核心产品与合作收入节奏对利润率的影响。上季度公司实现营收38.84亿美元，同比增长2.51%，毛利率43.09%，归属于母公司股东的净利润为8.45亿美元，净利率21.74%，调整后每股收益11.44美元，同比下降5.22%。综合这些因素，机构普遍维持对再生元制药公司中期增长的正向判断，短期利润率的波动被视为可接受的阶段性现象。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118749575","title":"再生元制药公布Cemdisiran治疗GMG的三期Nimble试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118749575","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118749575?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:32","pubTimestamp":1776781935,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发药物Cemdisiran在针对全身性重症肌无力（GMG）的三期Nimble临床试验中取得积极成果。该试验达到主要终点和关键次要终点，显示药物能显著改善患者临床症状。Cemdisiran作为一款创新疗法，此次数据为其后续监管申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU1974910355.USD","LU0882574055.USD","LU0823434583.USD","LU2362541513.USD","LU0114720955.EUR","LU0823416689.USD","LU0289739699.SGD","LU0058720904.USD","LU2468319806.SGD","BK4588","LU2023250504.SGD","LU2237438978.USD","LU0053666078.USD","LU2362541273.HKD","LU2106854487.HKD","REGN","LU2362540622.SGD","LU2089984988.USD","LU0823434740.USD","LU1917777945.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179614202","title":"Cemdisiran每12周皮下注射一次，在全身型重症肌无力三期试验中展现快速、深度且持久的疾病控制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1179614202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179614202?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:30","pubTimestamp":1776781822,"startTime":"0","endTime":"0","summary":"再生元制药公司研发的Cemdisiran在最新三期临床试验中取得突破性进展。该药物采用每12周一次皮下注射的给药方案，针对全身型重症肌无力患者展现出卓越的治疗效果。\n临床数据显示，Cemdisiran能够实现快速起效、深度缓解并维持长期疾病控制。这种创新疗法为患者提供了更为便捷的治疗选择，显著改善了用药依从性。\n试验结果证实，Cemdisiran在关键疗效指标上均表现出显著优势，为全身型重症肌无力的治疗开辟了新途径。该药物的长效特性有望重塑现有治疗格局，为患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0114720955.EUR","BK4588","LU0889565916.HKD","LU0289739699.SGD","LU0109394709.USD","LU0053666078.USD","LU2362540622.SGD","LU2362541273.HKD","REGN","BK4585","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU2023250504.SGD","LU2106854487.HKD","LU0823434583.USD","BK4139","LU0823434740.USD","LU1974910355.USD","LU0058720904.USD","LU1917777945.USD","LU2237438978.USD","LU2362541513.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756325.SGD","02196","NVOH","BK4588","LU0154236417.USD","BK4585","688177","BK4599","300558","BK4532","603087","301087","LU1093756168.USD","NVO","600513","002437","NVOX","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","REGN","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182410565","title":"再生元制药公司向TELIX支付4000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1182410565","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182410565?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:33","pubTimestamp":1776076393,"startTime":"0","endTime":"0","summary":"根据最新合作协议，TELIX PHARMACEUTICALS LTD将获得来自再生元制药公司的一笔总额为4000万美元的预付款项。此次交易标志着两家生物技术企业在创新药物研发领域的重要合作进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","BK7067","LU2362541513.USD","LU2023250504.SGD","LU0289739699.SGD","LU0058720904.USD","LU0823434740.USD","LU2106854487.HKD","LU0882574055.USD","BK4588","LU0114720955.EUR","LU1917777945.USD","LU0823434583.USD","LU0320765992.SGD","LU2362541273.HKD","REGN","LU0823416689.USD","BK4585","LU2362540622.SGD","TLX.AU","LU2237438978.USD","LU2468319806.SGD","LU0889565916.HKD","LU1974910355.USD","LU2089984988.USD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173287378","title":"Telix制药有限公司将获4000万美元预付款及高达21亿美元里程碑款项加特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1173287378","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173287378?lang=zh_cn&edition=full","pubTime":"2026-04-13 06:29","pubTimestamp":1776032954,"startTime":"0","endTime":"0","summary":"Telix制药有限公司（ASX: TLX）宣布达成一项重大许可协议，根据协议条款，公司将获得4000万美元的预付款。此外，若未来达成特定的研发、监管和商业化里程碑，Telix还有资格获得总额高达21亿美元的款项。协议还包括基于未来产品销售的特许权使用费安排。此项交易凸显了Telix在放射性药物领域领先技术的价值及其产品的巨大市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU1917777945.USD","LU2362541273.HKD","LU2362540622.SGD","LU0823434583.USD","BK4588","LU2089984988.USD","BK4139","LU0823434740.USD","LU2468319806.SGD","LU0889565916.HKD","LU0882574055.USD","LU0053666078.USD","LU1974910355.USD","LU2023250504.SGD","BK7067","LU2362541513.USD","LU2237438978.USD","LU0823416689.USD","BK4585","LU0320765992.SGD","LU0109394709.USD","LU0289739699.SGD","LU2106854487.HKD","TLX.AU","LU0114720955.EUR","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625314946","title":"再生元 2025 年全年营收143.43亿美元  2026年研发费用预计最高达66.8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625314946","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625314946?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:53","pubTimestamp":1775649198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元制药 公布 2025 年第四季度及全年财务业绩。Q4 总收入 38.84 亿美元，同比增长 3%；全年总收入 143.43 亿美元，同比增长 1%。全年 GAAP 净利润 45.05 亿美元，同比增长 2%；GAAP 摊薄每股收益 41.48 美元，同比提升 8%。研发投入持续加码，2025 年研发费用 58.50 亿美元，同比增长 14%，DB-OTO、garetosmab 等重点品种预计 2026 年获批上市。公司同时发布 2026 年业绩指引：GAAP 研发费用预计 64.50 亿 - 66.80 亿美元，销售管理费用 28.60 亿 - 30.40 亿美元，产品毛利率 79%-80%，资本开支 11.00 亿 - 13.00 亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ODQyMGE4ZDAyNTIxMTM1NjQzNTI0MDc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODQyMGE4ZDAyNTIxMTM1NjQzNTI0MDc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2023250504.SGD","BK4139","LU0889565916.HKD","LU0109394709.USD","LU2362540622.SGD","LU0114720955.EUR","LU1917777945.USD","LU2237438978.USD","LU1974910355.USD","LU2089984988.USD","LU0053666078.USD","LU2362541513.USD","BK4588","LU0823416689.USD","LU0289739699.SGD","LU2468319806.SGD","LU0320765992.SGD","LU0823434740.USD","LU0882574055.USD","LU2106854487.HKD","REGN","LU0823434583.USD","LU0058720904.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145598359","title":"再生元制药公司预计2026年第一季度将录得1.02亿美元税前IPR&D费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1145598359","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145598359?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:08","pubTimestamp":1775646498,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，再生元制药公司披露，预计在2026年第一季度将产生一笔高达1.02亿美元的税前费用。\n此项费用将同时按照美国通用会计准则（GAAP）和非美国通用会计准则（Non-GAAP）进行列报，涉及的是IPR&D项目。IPR&D，即“已购入进程研发”，通常指企业在并购过程中获得的、尚未完成商业准备的研发项目资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0823434583.USD","LU2237438978.USD","LU0882574055.USD","LU0823434740.USD","LU0289739699.SGD","LU2468319806.SGD","LU0058720904.USD","LU0114720955.EUR","LU2089984988.USD","BK4139","LU0109394709.USD","LU1974910355.USD","LU2362541513.USD","LU0320765992.SGD","LU1917777945.USD","LU2023250504.SGD","LU0889565916.HKD","LU2106854487.HKD","REGN","LU2362541273.HKD","LU0823416689.USD","LU2362540622.SGD","LU0053666078.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117796350","title":"再生元制药公司：作为合作一部分，将向Trinetx投资高达2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117796350","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117796350?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:32","pubTimestamp":1775161930,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，作为双方战略合作的一部分，公司将向Trinetx进行最高达2亿美元的投资。这一举措旨在深化双方在医疗数据领域的协作，共同推进精准医疗的创新与发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU1974910355.USD","LU0882574055.USD","LU0823434583.USD","LU2362541513.USD","LU0114720955.EUR","LU0823416689.USD","LU0289739699.SGD","LU0058720904.USD","LU2468319806.SGD","BK4588","LU2023250504.SGD","LU2237438978.USD","LU0053666078.USD","LU2362541273.HKD","LU2106854487.HKD","REGN","LU2362540622.SGD","LU2089984988.USD","LU0823434740.USD","LU1917777945.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106317031","title":"TriNetX与再生元制药达成合作，获取3亿患者去标识化电子健康记录，推动生命科学及数字健康解决方案研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1106317031","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106317031?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:30","pubTimestamp":1775161816,"startTime":"0","endTime":"0","summary":"TriNetX与再生元制药公司（Regeneron Pharmaceuticals）宣布建立合作关系，将获取多达3亿患者的去标识化电子健康记录。这一战略性合作旨在加速生命科学领域的研究进程，并推动数字健康解决方案的产品开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0823434583.USD","BK4588","REGN","LU0114720955.EUR","LU0289739699.SGD","LU2468319806.SGD","LU0823434740.USD","LU2237438978.USD","LU0882574055.USD","LU0320765992.SGD","LU0109394709.USD","LU1974910355.USD","LU2362541273.HKD","LU0823416689.USD","LU0058720904.USD","LU1917777945.USD","BK4139","LU0889565916.HKD","LU0053666078.USD","BK4585","LU2023250504.SGD","LU2106854487.HKD","LU2362541513.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155662129","title":"再生元Eylea Hd®获FDA批准 成为首个且唯一一款治疗湿性年龄相关性黄斑变性与糖尿病黄斑水肿、注射间隔长达5个月的抗VEGF药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1155662129","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155662129?lang=zh_cn&edition=full","pubTime":"2026-04-03 00:01","pubTimestamp":1775145702,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准再生元制药公司的Eylea Hd®（阿柏西普）上市。该药物成为目前首个也是唯一一个可用于湿性年龄相关性黄斑变性（WAMD）和糖尿病黄斑水肿（DME）治疗、且给药间隔可延长至5个月的注射用抗VEGF疗法。这一批准为患者提供了更长效的治疗选择，有望减轻频繁注射的负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU2362541273.HKD","LU0889565916.HKD","LU2362541513.USD","LU0320765992.SGD","LU2237438978.USD","LU0109394709.USD","BK4588","LU2089984988.USD","BK4139","LU2468319806.SGD","LU1974910355.USD","BK4585","REGN","LU0058720904.USD","LU0053666078.USD","LU0823434740.USD","LU2106854487.HKD","LU0289739699.SGD","LU0114720955.EUR","LU0823434583.USD","LU2023250504.SGD","LU0823416689.USD","LU2362540622.SGD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120065420","title":"Dupixent®（Dupilumab）获日本批准，成为首个治疗成人天疱疮（BP）的靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1120065420","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120065420?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:01","pubTimestamp":1774332107,"startTime":"0","endTime":"0","summary":"Dupixent®（Dupilumab）近日在日本获得监管批准，这是该国首个用于治疗成人天疱疮（BP）的靶向药物。这一里程碑式的批准为患有这种罕见且严重的自身免疫性皮肤病的成年患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0320765992.SGD","LU2089984988.USD","LU0882574055.USD","LU0114720955.EUR","LU0053666078.USD","LU2468319806.SGD","BK4588","LU1917777945.USD","LU2023250504.SGD","LU0823434583.USD","LU0289739699.SGD","LU0823434740.USD","LU1974910355.USD","LU0889565916.HKD","BK4585","LU2362540622.SGD","LU2362541273.HKD","LU2237438978.USD","LU2106854487.HKD","LU0058720904.USD","LU0823416689.USD","LU0109394709.USD","REGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121226589","title":"FDA确认2025年11月19日获批的Eylea Hd补充申请符合优先审评券兑换标准","url":"https://stock-news.laohu8.com/highlight/detail?id=1121226589","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121226589?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320790,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日裁定，针对再生元制药公司Eylea Hd药品的补充申请——该申请已于2025年11月19日获得批准——完全符合兑换优先审评券的资格条件。这一决定意味着再生元公司可凭借此次获批的补充申请，行使优先审评券赋予的加速审评权益。\n优先审评券制度旨在激励药企研发针对特定疾病的创新疗法，允许企业将券用于其他在研药物的审评流程，从而显著缩短审批时间。Eylea Hd作为再生元旗下的重要眼科治疗产品，此次补充申请的获批及符合兑换标准，不仅强化了该产品的市场地位，也为企业后续产品线的加速推进创造了有利条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU1974910355.USD","LU0882574055.USD","LU0823434583.USD","LU2362541513.USD","LU0114720955.EUR","LU0823416689.USD","LU0289739699.SGD","LU0058720904.USD","LU2468319806.SGD","BK4588","LU2023250504.SGD","LU2237438978.USD","LU0053666078.USD","LU2362541273.HKD","LU2106854487.HKD","REGN","LU2362540622.SGD","LU2089984988.USD","LU0823434740.USD","LU1917777945.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160965279","title":"FDA批准Eylea Hd治疗罕见儿科疾病 兑现优先审评券","url":"https://stock-news.laohu8.com/highlight/detail?id=1160965279","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160965279?lang=zh_cn&edition=full","pubTime":"2026-03-12 21:06","pubTimestamp":1773320784,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准再生元制药公司（Regeneron Pharmaceuticals）的Eylea Hd用于治疗一种罕见儿科疾病。作为此次批准的一部分，再生元制药公司成功兑现了其持有的优先审评券，该举措旨在加速创新疗法的审评流程。\n此次批准标志着Eylea Hd在罕见儿科疾病治疗领域迈出了重要一步。优先审评券的兑现进一步凸显了该疗法在满足未竟医疗需求方面的潜力，为相关患者群体带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2237438978.USD","BK4139","LU0889565916.HKD","LU2362541513.USD","LU2362540622.SGD","LU0823434740.USD","LU2468319806.SGD","LU0289739699.SGD","LU0058720904.USD","LU1974910355.USD","LU0882574055.USD","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0114720955.EUR","LU2023250504.SGD","LU0823416689.USD","LU2106854487.HKD","LU1917777945.USD","LU2089984988.USD","LU0823434583.USD","REGN","BK4588","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4121","IE00BKVL7J92.USD","LU0128526141.USD","AZN","BK4007","NVO","NVOX","LU1815336091.USD","BK4599","LU1093756168.USD","IE00BFMHRM44.USD","BK4588","IE00BZ1G4Q59.USD","BK4530","BK4532","NVOH","INCY","LU0154236417.USD","LU0390134368.USD","REGN","LU0757428866.USD","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173776344","title":"再生元授权肥胖治疗药物Olatorepatide在中国患者中展现积极三期临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1173776344","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173776344?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:05","pubTimestamp":1773054309,"startTime":"0","endTime":"0","summary":"再生元制药公司授权的肥胖治疗药物Olatorepatide，近日在中国患者群体中完成的三期临床试验显示出积极疗效。该研究结果标志着这一创新疗法在亚洲人群中的临床应用取得重要进展，为肥胖症治疗领域注入新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2468319806.SGD","LU2362541513.USD","LU2362540622.SGD","REGN","BK4585","LU0114720955.EUR","LU2023250504.SGD","LU0889565916.HKD","BK4139","LU0109394709.USD","LU2089984988.USD","BK4588","LU2237438978.USD","LU0823434583.USD","LU0320765992.SGD","LU0289739699.SGD","LU0882574055.USD","LU0053666078.USD","LU2362541273.HKD","LU0823416689.USD","LU1974910355.USD","LU0823434740.USD","LU2106854487.HKD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120176878","title":"再生元制药公司：Olatorepatide治疗患者在48周内实现高达19%的体重减轻","url":"https://stock-news.laohu8.com/highlight/detail?id=1120176878","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120176878?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054229,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的最新数据显示，接受Olatorepatide治疗的患者在第48周时体重减轻幅度最高达到19%。这一结果凸显了该药物在体重管理领域的显著疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU0823434740.USD","LU2362540622.SGD","LU0053666078.USD","LU2237438978.USD","LU2362541273.HKD","LU0058720904.USD","LU0889565916.HKD","LU0289739699.SGD","LU1974910355.USD","LU0320765992.SGD","BK4585","LU0823416689.USD","LU0109394709.USD","REGN","LU2023250504.SGD","LU0114720955.EUR","LU1917777945.USD","LU0823434583.USD","LU2468319806.SGD","LU2362541513.USD","LU0882574055.USD","LU2106854487.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148298032","title":"再生元制药公司计划今年晚些时候启动Olatorepatide全球三期注册项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1148298032","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148298032?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054148,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，将于今年晚些时候正式启动其候选药物Olatorepatide的全球三期注册临床试验项目。这一关键性研究旨在评估该药物在目标适应症中的疗效与安全性，标志着Olatorepatide的研发进程迈入商业化前的最终阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4585","LU0114720955.EUR","LU2362541513.USD","LU0823434740.USD","LU2023250504.SGD","LU0882574055.USD","LU1917777945.USD","LU2237438978.USD","BK4588","LU0109394709.USD","REGN","LU0289739699.SGD","LU1974910355.USD","LU2468319806.SGD","LU0889565916.HKD","BK4139","LU2106854487.HKD","LU0058720904.USD","LU0823434583.USD","LU0823416689.USD","LU2362540622.SGD","LU2362541273.HKD","LU2089984988.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197814779","title":"再生元制药公司：Olatorepatide展现良好胃肠道耐受性，不良事件发生率更低","url":"https://stock-news.laohu8.com/highlight/detail?id=1197814779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197814779?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:01","pubTimestamp":1773054106,"startTime":"0","endTime":"0","summary":"再生元制药公司近日公布的研究数据显示，其研发的Olatorepatide在临床试验中表现出优异的胃肠道耐受特性，且不良事件发生率显著低于预期。\n该药物在安全性方面的积极结果为其后续开发奠定了良好基础，有望为相关疾病治疗提供新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU2362541513.USD","LU0058720904.USD","LU0823434583.USD","LU0823416689.USD","LU2468319806.SGD","LU0109394709.USD","REGN","LU2106854487.HKD","LU0889565916.HKD","LU2237438978.USD","BK4139","BK4588","LU0114720955.EUR","LU2362541273.HKD","LU0320765992.SGD","LU0823434740.USD","LU2089984988.USD","LU0882574055.USD","LU0289739699.SGD","LU2023250504.SGD","LU0053666078.USD","LU1917777945.USD","BK4585","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0667},{"period":"1month","weight":-0.0976},{"period":"3month","weight":-0.054},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1888},{"period":"ytd","weight":-0.0913}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.055661},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}